secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001104659-26-046861
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus appoints Douglas Swirsky as CFO, effective May 1, 2026
----------------------------------------------------------------

- Swirsky appointed Chief Financial Officer and principal accounting officer, effective May 1, 2026.
- Previously served as CFO of MaxCyte (2023-2026) and AavantiBio; CEO of Rexahn Pharmaceuticals.
- Compensation: $20,000 per month via master services agreement with Grand Strand BioAdvisors LLC.
- Company will provide D&O insurance and indemnification on terms no less favorable than other officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465926046861/0001104659-26-046861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465926046861/tm2612491d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-046861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer